Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Recurrence 4Multiple Myeloma 4Lymphoma 4Ovarian Neoplasms 3Burkitt Lymphoma 3Neoplasms, Plasma Cell 2Nasopharyngeal Carcinoma 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Solid Tumors 1Solid Tumor 1Solid Cancer 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1POEMS Syndrome 1Neuromyelitis Optica 1Neuroblastoma 1Neoplasms, Neuroepithelial 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myositis 1Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease 1Myasthenia Gravis 1Multiple Sclerosis 1Metastatic Castration-resistant Prostate Cancer 1Melanoma 1Lymphoma, Mantle-Cell 1

Interventions

spartalizumab 1selicrelumab 1fludarabine 1Sunitinib 1Sirolimus 1Interleukin-2 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Solid Tumors × fludarabine × Clear all
NCT05648994 2022-12-13

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Fujian Cancer Hospital

Phase EARLY_PHASE1 Unknown
30 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡